CTLA4 and melanoma: To study the effect of the systemic IL-17A level on the anti-tumor efficacy of ICI therapy in vivo, we used two syngeneic melanoma transplantation models with distinct genotypes and response profiles to experimentally administered anti-CTLA-4 and anti-PD-1 antibodies20,21.